TMO · Q1 2026 Earnings

Bullish

Thermo Fisher Scientific

Reported April 23, 2026

30-second summary

Q1 revenue grew 6% reported to $11.01B with organic growth of just 1% — exactly what CEO Casper telegraphed on the Q4 call — and adjusted EPS of $5.44 cleared the prior "low single-digit growth" qualitative bar. Clario closed March 24th (months earlier than the mid-2026 assumption baked into prior guidance), and management took FY2026 revenue to $47.3–$48.1B (+6–8% reported, organic held at 3–4%) and adjusted EPS to $24.64–$25.12 (+8–10%, up from +6–8%). The full Clario accretion is now in the base guide; what remains undone is the organic acceleration from 1% in Q1 to ~4%+ exit-rate required to hit the FY.

Headline numbers

EPS

Q1 FY2026

$5.44

Revenue

Q1 FY2026

$11.01B

+6.0% YoY

Gross margin

Q1 FY2026

40.7%

Free cash flow

Q1 FY2026

$0.82B

Operating margin

Q1 FY2026

16.9%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$11.01B	+6.0%	$12.21B	-9.9%
EPS	$5.44	—	$6.57	-17.2%
Gross margin	40.7%	—	41.5%	-80bps
Operating margin	16.9%	—	18.5%	-160bps
Free cash flow	$0.82B	—	$3.02B	-72.7%

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q1 FY2026	A couple of points lower than full year 2026 organic growth (3-4% FY), implying ~1-2% organic	11.01B	+6% YoY reported (above the low end of prior FY 4-6% guide; Q1 organic 1% in-line with prior qualitative guidance of 1-2%)	Beat
Adjusted EPS	Q1 FY2026	Low single-digit growth	5.44	Above low single-digit growth expectation	Beat

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY2026	$46.3 to $47.2 billion	$47.3 to $48.1 billion	+$0.1B to +$0.9B (midpoint raised $0.95B from $46.75B to $47.7B)	Raised
Adjusted EPS Growth	FY2026	6% to 8%	8% to 10%	+200 basis points (both low and high end raised 200bps)	Raised
Adjusted EPS (absolute)	FY2026	$24.22 to $24.80	$24.64 to $25.12	+$0.42 to +$0.32 (midpoint raised from $24.51 to $24.88, +$0.37)	Raised
Reported Revenue Growth	FY2026	4% to 6%	6% to 8%	+200 basis points (both ends raised 200bps)	Raised
Adjusted Operating Margin Expansion	FY2026	50 basis points	70 basis points	+20 basis points	Raised
Net Interest Expense	FY2026	~$500 million	~$660 million	+~$160 million	Raised
Net Capital Expenditures	FY2026	$1.8 to $2.0 billion	$1.9 to $2.1 billion	+$0.1B to +$0.1B (both ends raised by $100M)	Raised
Free Cash Flow	FY2026	$6.8 to $7.3 billion	$6.9 to $7.4 billion	+$0.1B to +$0.1B (midpoint raised from $7.05B to $7.15B, +$0.	Raised

Reaffirmed unchanged this quarter: Organic Revenue Growth (3% to 4%)

Segment KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
Life Sciences Solutions	$2.636B	+12.6%
Analytical Instruments	$1.716B	-0.1%
Specialty Diagnostics	$1.142B	-0.5%
Laboratory Products and Biopharma Services	$6.036B	+7.0%

Other KPIs

Q1 FY2026

Segment	Q1 FY2026
Adjusted Operating Margin	21.8%
Organic Revenue Growth	1%
Life Sciences Solutions Segment Margin	36.2%
Analytical Instruments Segment Margin	20.7%
Specialty Diagnostics Segment Margin	27.4%
Laboratory Products and Biopharma Services Segment Margin	12.9%

Management tone

Q1-25 macro defensiveness → Q2-25 explicit 2026–2027 valley framework → Q3-25 execution-driven raise → Q4-25 quantified 2026 inflection → Q1-26 active management through inflation while raising guidance.

Three quarters ago tariffs were a 140bps margin headwind requiring mitigation; two quarters ago they delivered $0.11 of unexpected upside; last quarter Casper described them as a competitive advantage; this quarter management quantifies "approximately 80 basis points of headwind from tariffs and related FX" in Q1 and notes the FY guide "includes 20 basis points of additional margin expansion" — tariffs are now a quantified, embedded variable in a positive margin framework, not a risk factor. The receipt is the +70bps FY operating margin expansion guide (up from +50bps), absorbed alongside higher inflation assumptions.

The "trusted partner" framing has fully replaced the prior "unparalleled commercial engine" language around M&A. Casper on Clario: "further strengthens Thermo Fisher's position as the trusted partner to pharma and biotech customers." This is the third consecutive quarter where M&A is positioned around customer intimacy and clinical-workflow integration rather than portfolio optimization or revenue accretion. The strategic implication: management is underwriting Clario primarily as switching-cost creation, not as a financial transaction — and the early March 24 close (vs. mid-2026 assumption) means Clario added $0.32 of adjusted EPS net of financing costs to the FY guide (per CFO Jim Meyer), substantially better than the prior $0.20–$0.25 partial-year assumption and the primary explanation for the +$0.37 midpoint EPS raise.

The macro language inverted from Q4's "position of strength" framing into a more active-management posture: "our end markets are progressing in line with our expectations" paired with "actively managing the company and drive excellent operational performance, enabling us to increase our guidance for the year while navigating a complex macro environment." The shift from "position of strength" to "navigating complex macro" is subtle but real — management has stopped claiming the macro is benign and is instead claiming the response to a difficult macro is what's working. That is less of a victory lap than Q4.

PPI continues its trajectory from operational tool (Q2-25) → moat (Q3-25) → AI-multiplied moat (Q4-25) → cultural resilience mechanism (Q1-26). Casper: "The mindset of finding a better way every day is a core part of our culture and gives me great confidence in our ability to manage through the current environment." PPI is now framed less as a process and more as an existential cultural advantage — the rhetorical work being done is to convince investors that execution can outrun the organic growth gap.

The unresolved tension: organic growth of 1% in Q1 with the FY held at 3–4% requires acceleration to ~4.5%+ exit-rate, and Analytical Instruments — the segment that needed to re-accelerate to underwrite the build — went the other way. Management's Q2 organic guide of ~3% is consistent with the prior quarterly progression framework, but the implied H2 rate now needs to be higher than originally telegraphed.

Recurring themes management leaned on this quarter:

Trusted partner status via integrated service offerings (Clario, SHL collaboration, accelerated drug development)High-impact innovation launching across all segments (Glacios III CryoEM, TSQ-CIRTIS, COPLIO)Active management and PPI system driving productivity to offset macro headwindsStrategic M&A execution (Clario, Soventa filtration, SHL partnership) strengthening competitive positionCapital discipline: raising guidance while deploying $3B buybacks and 10% dividend increaseResilience narrative: end markets and customers will prove resilient despite Middle East complexity and inflation

Risks management surfaced:

Middle East conflict creating modest inflationary pressureMuted macro conditions in US and China impacting academic and government end marketTariff and FX headwinds (80 basis points in Q1, partially offset by productivity)One less selling day in Q1 impacting organic growth by ~100 basis pointsUnfavorable product mix in multiple segments (analytical instruments, lab products)

Q&A highlights

Michael Riskin · Bank of America

Investor concerns about revenue acceleration needed through the year to hit full-year guidance, particularly regarding Q3-Q4 ramp assumptions given macro pressures and end market concerns.

Management emphasized that Q1 results were as expected and the ramp is driven by comparable days and technical factors, not changes in underlying market conditions. Macro is challenging but not in customers' thinking; they're focused on pipelines and scientific advances. Q2 will benefit from day comparisons and changes in analytical instruments comparables.

Q1 organic growth: 1%Q2 expected organic growth: 3%Ramp driven by comparable days impact and pharma services phasing, not market condition changesPharma and biotech delivering strongest end market growth as expected

Tycho Peterson · Jefferies

Questions on PPD clinical research business momentum given peer light bookings, biotech funding translating to spending, and early customer feedback on Clario acquisition.

Clinical research had excellent quarter with sequential and YoY organic growth improvement. Customers value capabilities and management seeing share gain momentum. Biotech funding environment improving. Clario acquisition closed March 24th with early positive customer feedback on technology and ability to simplify clinical trial execution. Company embedding AI into accelerated drug development capabilities.

Clinical research had excellent quarter with sequential step-up in organic growthStrong growth in both revenue and authorizations YoYBiotech funding environment improvingClario closed March 24, customers excited about technology

Jack Meehan · Nefron Research

Impact of AI adoption on customer spending behavior across business segments and new AI-leveraging offerings coming at analyst day May 20th.

AI accelerating scientific discovery and drug development, expected to improve ROI for drug development industry and increase biotech funding interest. Company positioned across clinical research, technology, instrument, and life science solutions businesses to benefit. AI amplifies Thermo Fisher's competitive advantages: scale, portfolio breadth, trusted partner status. Analyst day scheduled for May 20th.

Analyst day scheduled for May 20th in New YorkAI expected to improve drug development ROIAI integration across clinical research, instruments, technology, life science solutionsOpenAI and NVIDIA partnerships driving AI capabilities

Matt LaRue · William Blair

How AI-driven experimentation scaling and autonomous labs requiring enhanced automation, connectivity, and auditability will influence instrument development strategy and customer usage patterns.

AI driving large-scale biologic data generation for model-building at scale, not just focused research. Customers increasingly want instruments to be automation-ready with seamless data population into models. Company aware of trend for years (lab of the future concept); scale facilities coming online adopting their technologies. R&D roadmap focused on better connectivity; confident in approach. Reshoring activity is tailwind for 2027-28 with contracts already signed in CDMO; some brownfield facility scaling revenue appearing earlier.

Automation-ready instruments increasingly demanded for large-scale biology model generationReshoring revenue expected primarily in 2027-28Contracts already signed for reshoring opportunitiesSome brownfield facility scaling increasing confidence in near-term revenue

Dan Brennan · TD Cowan

Preclinical pharma and biotech business performance, whether it's been a drag, and outlook for improvement given limited MSN/IRA investment. Also on U.S. academic and government bottoming and recovery timeline.

Preclinical/lab-based pharma and biotech showing good momentum in higher-tech life science reagents portfolio, with some softness in lower-tech offerings but still progressing. Management seeing signs of pickup and feels okay about progression. U.S. academic and government conditions muted as expected in Q1, but budget passage in late January and improving funding flow are positive signs. Assuming greater stability and modest improvement over year, not return to normal.

Good momentum in higher-tech life science reagents channelSome softness in lower-tech offerings but progressingU.S. budget passage in late January positiveFunding flow starting to improve in Q1

Answers to last quarter's watch list

Did Q1 organic growth come in at ~1% without triggering a guidance walk-down? Yes. Organic growth landed at 1%, exactly the level Casper confirmed in Q4 Q&A, and the FY organic guide was reaffirmed at 3–4%. The reported guide was raised, but entirely on Clario M&A — the organic credibility test is met for now, though the implied back-half exit rate has gotten steeper. Status: Resolved positively

Did Clario close by mid-2026 with the partial-year accretion formally added to the FY guide? Yes, and substantially better than guided. Clario closed March 24th — months earlier than the mid-2026 assumption — and management quantified the contribution as $0.32 of adjusted EPS net of financing costs added to the FY2026 guide, vs. the prior $0.20–$0.25 partial-year assumption. This is the primary driver of the +200bps FY adjusted EPS growth raise to 8–10%, hitting the long-term 7%+ algorithm. Status: Resolved positively

Adjusted operating margin progression toward the +50bps FY2026 expansion target. Better than the watch threshold: FY expansion guide raised to +70bps (vs. prior +50bps). Q1 reported adjusted operating margin of 21.8% absorbs an 80bps tariff/FX headwind, so the YoY math is not directly observable from the print, but the raised FY framework signals confidence. Status: Resolved positively

FCF recovery vs. the $6.8–$7.3B FY guide; conversion ratio in Q1 specifically. Q1 FCF of $0.83B is a modest start — implies ~$6.1B run-rate, below even the prior FY guide low end. The FY guide was raised $100M to $6.9–$7.4B, signalling confidence in back-half conversion, but Q1 itself does not prove it. Conversion ratio against $1.65B Q1 net income is ~50%, below the FY implied conversion needed. Status: Continue monitoring

Analytical Instruments trajectory — does it re-accelerate as academic/government caution abates? No. AI went from +4.7% Q3-25 → flat Q4-25 → flat reported / -2% organic Q1-26 — three consecutive quarters of deceleration. Management's Q&A pointed to U.S. academic/government remaining muted with "modest improvement over year" expected, not a return to normal. This is the cleanest negative read in the print and directly contradicts what was supposed to underwrite the 3–4% FY organic build. Status: Resolved negatively

China commentary — does the mid-single-digit decline assumption hold? Partially addressed. Q&A confirmed China declined low single digits in Q1 (better than the mid-single-digit assumption), with pharma/biotech performing well and academic/government muted. Casper called himself "incrementally more positive" post-March visit but the guide assumes no meaningful China growth this year. Status: Continue monitoring

What to watch into next quarter

Whether Q2 organic growth delivers the guided ~3% — this is the first quarter where the FY 3–4% build needs to start showing up in the print rather than being deferred to H2. A miss puts the FY organic reaffirmation under serious pressure.

Analytical Instruments inflection — three sequential quarters of deceleration to -2% Q1 organic. The segment needs to turn positive in Q2 on the easier tariff-impacted comp, or the FY organic guide gets walked at Q3. Watch mass spec, cryo-EM, and chromatography sub-segment commentary at the May 20 analyst day.

Whether the LPBS segment margin of 12.9% (down ~160bps from Q4's 14.5%) was a Clario one-week consolidation artifact or reflects a structural mix shift; clean comp comes in Q2 with a full quarter of Clario contribution.

FCF conversion trajectory — Q1 conversion of ~50% needs to materially improve to hit the raised $6.9–$7.4B FY guide. Working-capital normalization from the FY2025 miss is the implicit assumption; if Q2 conversion doesn't step up meaningfully, the FY FCF guide is at risk again.

May 20 analyst day disclosures on the AI partnership architecture (OpenAI, NVIDIA) and any longer-term growth-algorithm reaffirmation — Casper's prior framing has the 7%+ rate returning after the 2026–2027 valley, and the analyst day is the natural venue to either re-anchor or quietly drop that commitment.

Reshoring revenue recognition timing — Q&A confirmed contracts are signed with most revenue in 2027–28 but "some brownfield facility scaling revenue appearing earlier." Watch Q2 LPBS commentary for any pull-forward signal.

Sources

Thermo Fisher Q1 2026 Earnings 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/97745/000009774526000086/q12026earnings8kex99_1.htm
Thermo Fisher Q1 2026 earnings call commentary (Mark Casper, Jim Meyer, and analyst Q&A as captured in extraction inputs)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.